The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): Results from a phase II prospective trial.
R. Rouzier
Honoraria - Roche
E. Lambaudie
No relevant relationships to disclose
J. Pierga
Consultant or Advisory Role - Roche
Research Funding - Roche
T. Petit
No relevant relationships to disclose
T. Delozier
No relevant relationships to disclose
J. Ferrero
No relevant relationships to disclose
M. Campone
No relevant relationships to disclose
J. Gligorov
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
F. Lerebours
No relevant relationships to disclose
H. Roche
No relevant relationships to disclose
D. Pau
Employment or Leadership Position - Roche
P. Viens
No relevant relationships to disclose
R. J. Salmon
No relevant relationships to disclose